October 2026 | Ocular Oncology
Winning the Battle for Life, Eye, and Vision
The field has evolved substantially to offer treatments for uveal melanoma beyond enucleation, but we still have far to go in preserving vision.
Antonio Bechara Ghobril, MD, FEBOophth, FMH; Salaam Botros, MBBS; and Carol L. Shields, MD
July/August 2026 | Ocular Oncology
PVRL: When “Uveitis” Is Not Uveitis
A steroid-responsive, uveitis-presenting phenotype was ultimately diagnosed as primary vitreoretinal lymphoma.
Andreas Theocharis, MD; Romy Bejjani, MD; and Erin E. Flynn, MD
November/December 2025 | Ocular Oncology
Choroidal Metastasis From Lung Adenocarcinoma
Diagnosis of choroidal malignancy should prompt a workup for systemic disease in patients with no known history of cancer.
Weilin Song, MD; Julie K. Kwon, MD; Basil K. Williams Jr, MD; and Jayanth Sridhar, MD
September 2025 | Ocular Oncology
Reducing Chemotherapy Duration for High-Risk Retinoblastoma
Three cycles may offer comparable clinical benefit to six cycles while reducing treatment burden.
Madison M. Woods, BA; Robert J. Medina, BA; and Carol L. Shields, MD
July/August 2025 | Ocular Oncology
Surgical Management of Retinal Detachment in Uveal Melanoma
Addressing this complication requires careful planning and follow-up.
Rodrigo Anguita, MBBS, MD, FEBO, FICO, and Lyndon da Cruz, MA, MBBS, PhD, FRCOphth, FRACO
March 2025 | Ocular Oncology
Neoplastic Masqueraders of Uveitis
Remember these various ocular malignancies as you prepare your differential diagnosis.
Ioanna Ploumi, MSc; Konstantina Riri, MD, MSc; and Sofia Androudi, MD, PhD
January/February 2025 | Ocular Oncology
Does Iris Color Matter in Uveal Melanoma?
Research confirms that light eyes are a risk factor.
Charles DeYoung, BA; Alexandra R. Zaloga, BA; Rolika Bansal, MD; and Carol L. Shields, MD
October 2024 | Ocular Oncology
Tissue Glue-Assisted Plaque Radiotherapy for Uveal Melanoma
A potentially safer approach for eyes with a thin sclera.
Robert J. Medina, BA; Madison M. Woods, BA; Rolika Bansal, MD; and Carol L. Shields, MD
September 2024 | Ocular Oncology
Combination Therapy for Metastatic Uveal Melanoma
A look at the response of large choroidal metastatic melanoma to treatment with darovasertib and crizotinib.
Lauren B. Yeager, MD, and Brian P. Marr, MD
July/August 2024 | Ocular Oncology
A Masquerade: Leukemia Retinopathy or Viral Infection?
Ocular symptoms thought to be related to malaria turned out to be signs of systemic malignancy.
Brian Wollocko, MD; Samuel Gelnick, MD; and Eric Shrier, DO, FAAO
April 2024 | Ocular Oncology
Ocular Effects of CAR-T Cell Therapy
Know the risks and potential therapeutic benefits associated with this treatment modality.
Lars H. Andersen, MD; Jaskirat S. Takhar, MD; and Jose J. Echegaray, MD
March 2024 | Ocular Oncology
Conditional Survival of Patients With Uveal Melanoma
Factoring in years of metastasis-free survival may lead to an improved prognosis.
Harrison S. Fellheimer, BA; Madison M. Woods, BA; Joseph D. DeSimone, BS; and Carol L. Shields, MD
January/February 2024 | Ocular Oncology
Ocular Toxicity of New-Age Cancer Therapies
Because modern medications may induce immune-related ocular adverse events, a collaborative approach is important when caring for these patients.
Ronak Shah, BS; Robin A. Vora, MD; Amar Patel, MD; and Ying Qian, MD
October 2023 | Ocular Oncology
Choroidal Melanoma: Does Skin Tone Matter?
The literature shows that Fitzpatrick skin type can affect the prognosis and outcomes of cancers.
Irwin Leventer, BA; Kevin R. Card, BS; and Carol L. Shields, MD
March 2023 | Ocular Oncology
Beware of Congenital Pigmented Ocular Findings
These could indicate overlooked oculodermal melanocytosis, or nevus of Ota, a risk factor for uveal melanoma.
Devon Shatzman, BS; Mrittika Sen, MD; and Carol L. Shields, MD
November/December 2022 | Ocular Oncology
Intraarterial Chemotherapy for Recurrent Retinoblastoma
An excellent option for primary and secondary therapy.
Rachel S. Kim, BS; Kushal U. Agrawal, MS; and Carol L. Shields, MD
October 2022 | Ocular Oncology
Hemorrhage Over a Choroidal Nevus—Harmless or Hazardous?
Choroidal neovascularization may lead to worrisome findings on fundus autofluorescence, but these do not necessarily indicate malignancy.
Samantha Pastore, BS; Jennifer S. Zeiger, BA; Guy S. Negretti, FRCOphth; and Carol L. Shields, MD
April 2022 | Ocular Oncology
Trilateral Retinoblastoma with Suprasellar Mass
A rare case was effectively treated with high-dose chemotherapy and autologous stem cell rescue.
Catherine K. Liu, BS; Zeynep Bas, MD; and Carol L. Shields, MD
View More Articles